This stock is breaking out. We’ve seen these levels before, but not for a couple of years. This stock has been a spotty trader, in terms of volume. There was a good consolidation at $6.50 and it looks to be coming off of that. The volume on the recent upside swing looks good. It might rise to $8 or 9 over the next 6 months. It pays a very small dividend. In terms of fundamentals, it looks like a bargain right now. For example it looks good in terms of earnings and in terms of industry relative value. If it does fall, start reducing at $6.40 or $6.50 and use $5.85 for a full exit.

This is one of the top holdings in his Canadian equity fund. There will be some momentum tomorrow as it reports earnings. From a fundamental view, it is a buy from asset growth, earnings momentum, industry relative, etc. It looks great technically as well. His buying decisions are not primarily based on technical indicators but he looks at them, and this stock looks positive fundamentally and technically.

You might want to make a small purchase on this. It has been trading between $6 and $7.50, so it is near the lower end of that range now. At this level, you can think of this as a trading stock. Use a tight stop at $6. Generally he is negative about energy stocks at this point. There is a lot of risk with this, and not a lot of positive fundamentals. Be willing to sell quickly and expect to make about 50 cents. There are many other trading opportunities that he likes better and he would not be trading this.

(At the time of this comment, Aetna holders have just approved the deal with CVS.) This is a very large company. It’s underperforming most other large companies. It hit a solid bottom of about $66 and so it’s at a good buy point, $68, at the low end of its range. Volume is not terrific. You definitely want to get out if it falls below $66. If you buy this now, the first expectations would be a $4 gain, with potential rise of another $5 to $6. (Analysts’ price target is 80.21$)

Boasts 10-11x forward earnings with a 15% growth rate. FDA trial approvals would increase investor confidence further, but they have a good pipeline of products. Likes it longer term.

This looks like a normal consolidation on an upward cycle. It’s going to be tricky from a technical perspective. If you own it, you want to get out at $51 (It is at $54.55 today.) He has no problems with buying it here. If it can break out of this consolidation, it will go to $56, with a potential rise of another $3 or $4. He likes the movement of the stock so far.

This is an ultra-low cost airline. The airlines have been doing very well recently. The chart shows the company is transitioning from one kind of company to another at around mid-December. He likes very-low-price companies but would be cautious about how much he would invest. Not more than 3% of his portfolio. He would expect this company to trade like the early-stage marijuana companies, with a lot of jumps in price that are based on performance. From the chart, this looks like an ideal buying opportunity.